Duration of Dual Anti-Platelet Therapy (DUAL-ACS2)

Duration of Dual Anti-Platelet Therapy in Acute Coronary Syndrome in Scotland

Despite substantial evidence supporting the use of dual anti-platelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy. Recent evidence suggests that shorter durations of dual anti-platelet therapy are superior because the avoidance of atherothrombotic events is counterbalanced by the greater risks of excess major bleeding with apparent increases in all-cause mortality with longer durations. The investigators propose a Scotland-wide randomised controlled trial of 19,424 patients with acute coronary syndrome allocated to differing durations of dual anti-platelet therapy. In collaboration with the Farr Institute, the investigators will exploit NHS Scotland's unique and innovative electronic health record linkage infrastructure to track duration of therapy and clinical outcomes in a real-world, real-time, efficient and highly cost-effective trial. This has the potential to define treatment duration, settle a major outstanding international controversy, and influence modern cardiology practice across the world.

Duration of Dual Anti-Platelet Therapy (DUAL-ACS2)

Recruitment

Summary

Participation Requirements

Description

Tracking Information